S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Other Current Liabilities
ÂĄ19.7m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Current Liabilities
ÂĄ1.5B
CAGR 3-Years
-7%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Current Liabilities
ÂĄ1.8B
CAGR 3-Years
38%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Current Liabilities
ÂĄ1.9B
CAGR 3-Years
53%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Current Liabilities
ÂĄ2.5B
CAGR 3-Years
23%
CAGR 5-Years
55%
CAGR 10-Years
58%
Imeik Technology Development Co Ltd
SZSE:300896
Other Current Liabilities
ÂĄ121.8m
CAGR 3-Years
33%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Other Current Liabilities?
Other Current Liabilities
19.7m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Other Current Liabilities amounts to 19.7m CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
23%

Over the last year, the Other Current Liabilities growth was 50%. The average annual Other Current Liabilities growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been 23% over the past three years .

Back to Top